DaVita Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Javier J. Rodriguez
- Full Time Employees
- 76,000
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- 2000 16th Street Denver CO United States of America 80202
- IPO Date
- Oct 31, 1995
- CIK
- 0000927066
- Website
- davita.com
- Similar Companies
- Business
- DaVita Inc. DaVita Inc. provides kidney care services, primarily dialysis treatments for patients with chronic kidney failure and end-stage kidney disease; operates approximately 2,675 outpatient dialysis centers in the United States serving more than 200,000 patients and 367 centers in 11 other countries serving around 49,400 patients; offers related laboratory services, including routine tests for dialysis patients and other physician-prescribed tests; delivers home-based hemodialysis, hospital inpatient dialysis, and acute inpatient dialysis services; provides integrated kidney care and disease management through DaVita Integrated Kidney Care for risk-based arrangements; conducts clinical research via DaVita Clinical Research since 1985 across pharmaceutical and medical device development; supports nephrologists with technology solutions through DaVita Physician Solutions; and develops innovative health care solutions for kidney disease patients through DaVita Venture Group. The company, incorporated in 1994 and formerly known as DaVita HealthCare Partners Inc. until a 2016 name change, maintains world headquarters in Denver, Colorado, and generates the majority of revenues from Medicare and government-based programs while targeting commercial payers for higher margins; it holds a 37% share of the U.S. dialysis market and operates internationally across regions including Latin America, Europe, and Asia. DaVita Inc. recently expanded internationally through 2024 acquisitions from Fresenius Medical Care for $300 million, adding over 270 clinics in Brazil, Colombia, Chile, and Ecuador to become Latin America's largest dialysis provider; entered new markets in Ecuador and Chile while deepening presence in Colombia; refinanced debt with a new $1.9 billion Term Loan B-2 and $3.5 billion credit facilities including a $2 billion Term Loan A-2 and $1.5 billion revolving facility in 2025; issued $1 billion in senior notes due 2033; and reported Q3 2025 revenues of $3.42 billion amid volume challenges from flu season, Hurricane Helene, and a cyber incident.
Banking Giant, Three Other Top Stocks Make New Highs As Market Aims To Rebound
DaVita HealthCare (DVA) Exceeds Market Returns: Some Facts to Consider
DaVita HealthCare (DVA) Moves to Strong Buy: Rationale Behind the Upgrade
Best Value Stocks to Buy for June 11th
Best Growth Stocks to Buy for June 11th
DaVita Stock Gains From Integrated Kidney Care and CKCC Progress
Are Investors Undervaluing DaVita (DVA) Right Now?
4 Outpatient Home Health Stocks Benefiting From Industry Trends
Best Growth Stocks to Buy for June 9th
Best Value Stocks to Buy for June 9th
DaVita Expands Comprehensive Kidney Care Through Dialysis Services
DaVita HealthCare (DVA) Up 0.6% Since Last Earnings Report: Can It Continue?
Best Growth Stocks to Buy for June 4th
DaVita Gains 21.4% in Three Months: How Should You Play the Stock?
Best Growth Stocks to Buy for June 2nd
Why DaVita HealthCare (DVA) is a Top Momentum Stock for the Long-Term
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
Best Growth Stocks to Buy for May 26th
New Strong Buy Stocks for May 26th
Is DaVita (DVA) Stock Undervalued Right Now?